Celgene And Bluebird Bio Highlight Results From Ongoing Multicenter Phase 1 Study Of bb2121 Anti-BCMA CAR T Cell Therapy In Patients With Multiple Myeloma Published In New England Journal Of Medicine
Benzinga Newsdesk